Articles related to MULTIPLE SCLEROSIS (MS)

Panelists conclude that sNfL can be used as a biomarker to assess response totreatment in future trials. In the clinic setting, it could become valuable in directingtherapy; for example, in cases in which the patient is absent clinical signs of aggressiveMS and it’s unclear if they will benefit from infused, injected, or oral disease-modifyingtherapy.

In this Journal Club discussion, among participants in the vaccine-CD20-vaccine cohort, 100% of participants experienced a measurable response to a third dose of a COVID-19 vaccine compared with 18% in the CD20-vaccine cohort.

According to a study published online in Neurology, in the 6 months after a colorectal cancer (CRC) diagnosis, patients with multiple sclerosis (MS) have an increased risk of all-cause and cancer-specific death. Data were included for 338 MS cases and 1,352 controls without MS, matched for birth year, sex, cancer diagnosis year, and region.

An extremely interesting case in New York is examined in this article, which chronicles a female patient suffering from multiple sclerosis and her suit against her neurologist for prescribing a new medication that her attorney feels goes beyond medical malpractice and into fraud under NY’s General Business Law 349: “deceptive acts or practices in the conduct of any business, trade or commerce or in the furnishing of any service in this state are hereby declared unlawful.”